Enzyvant Therapeutics Gmbh

Biopharmaceutical company

Based in MA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $700K in lobbying spend across 25 quarterly filings, Enzyvant Therapeutics Gmbh is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2018 to 2024.

$700K
Total Spend
7
Years Active
1
Firms Hired
8
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$130K
2019$120K
2020$120K
2021$120K
2022$120K
2023$90K
2024$0

Issues Lobbied

Health IssuesMedicare/Medicaid

Lobbying Firms

Jeffrey J. Kimbell & Associates, INC.

Lobbyists

Jeffrey KimbellJohn HerzogJodie LockhartKenneth HodgeKeith StuddardJohn RayDavid RudloffKelsey Carlson

Government Agencies Targeted

These are the government entities that Enzyvant Therapeutics Gmbh disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESOffice of Management & Budget (OMB)SENATEFood & Drug Administration (FDA)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid

Pharmaceutical and healthcare issues

Education about rare disease therapies

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Akebia Therapeutics, INC.
$9.8M total spend
Ardelyx, INC.
$9.4M total spend
Sage Therapeutics
$4.8M total spend
Organogenesis INC.
$4.0M total spend
Beone Medicines USA, INC (Formerly Beigene USA, INC.)
$3.5M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.